The Central Drugs Standard Control Organisation (CDSCO) has waived the requirement for local Phase 3 clinical trials for generic versions of lenacapavir, a breakthrough HIV prevention drug, moving India significantly closer to affordable long-acting HIV pre-exposure prophylaxis (PrEP). As reported by ThePrint on August 25, 2026, this regulatory waiver is expected to accelerate the availability of generic lenacapavir in the Indian market.
What the CDSCO Waiver Means
Lenacapavir, originally developed by Gilead Sciences and marketed as Sunlenca, is a first-in-class capsid inhibitor approved for HIV treatment and prevention. The drug’s key advantage is its dosing schedule: a single subcutaneous injection every six months, making it one of the most convenient PrEP options available.
Historically, generic manufacturers seeking to market a copy of an approved drug in India have been required to conduct local Phase 3 bioequivalence and clinical trials. The CDSCO’s waiver of this requirement for generic lenacapavir means manufacturers can rely on already-available global clinical data, substantially reducing the time and cost to bring a generic version to market.
Why This Matters for HIV Prevention in India
India has one of the world’s largest HIV-affected populations. According to National AIDS Control Organisation (NACO) estimates, hundreds of thousands of people in India are living with HIV, and PrEP is a critical tool for preventing new infections among high-risk groups.
Current daily oral PrEP options (tenofovir-based regimens) require consistent daily adherence, which can be challenging. A six-monthly injectable option like lenacapavir addresses this adherence gap directly. However, the branded version (Sunlenca) carries a price tag that puts it out of reach for most patients in low- and middle-income countries.
By enabling faster generic entry, the CDSCO waiver could dramatically lower the cost of long-acting PrEP in India, making it accessible to the populations that need it most.
DRL and Emcure Get Manufacturing Approval
On August 24, 2026, The Economic Times reported that Dr. Reddy’s Laboratories (DRL) and Emcure Pharmaceuticals have received approval to manufacture lenacapavir in India. This marks the first concrete step toward domestic production of the drug, complementing the CDSCO’s regulatory waiver.
Both DRL and Emcure are established Indian generic pharmaceutical companies with significant global footprints. DRL is known for its antiretroviral portfolio, and Emcure has a strong presence in women’s health and anti-infectives. Their involvement signals serious commercial intent to scale lenacapavir production for both domestic and export markets.
Global Context: Lenacapavir’s Regulatory Journey
Lenacapavir received its first FDA approval in December 2022 for multidrug-resistant HIV-1 infection, and a PrEP indication followed in 2025. The European Medicines Agency (EMA) has also approved the drug. The World Health Organization (WHO) has recognised long-acting injectable PrEP as a priority intervention in its HIV prevention guidelines, particularly for populations with adherence challenges to daily oral PrEP.
Gilead Sciences has pursued a voluntary licensing strategy for lenacapavir, partnering with generic manufacturers in India and other countries to expand access. The CDSCO’s waiver aligns with this global access framework, removing a regulatory bottleneck that could have delayed Indian generic entry by years.
What Buyers and Patients Should Know
For healthcare providers, procurement officers, and patients tracking the availability of generic lenacapavir in India, several practical points are worth noting:
- Timeline: With the Phase 3 waiver in place and manufacturing approvals granted, generic lenacapavir could reach the Indian market sooner than previously anticipated — potentially within 12–18 months, subject to final regulatory clearance and commercial scale-up.
- Verify manufacturing quality: When generic versions become available, buyers should verify WHO-GMP certification and CDSCO manufacturing approval before procurement. Not all manufacturers with approval will have identical quality systems.
- IMSDA’s verified member directory: For a list of verified and reliable pharmaceutical distributors, refer to the IMSDA’s verified member directory.
- Price expectations: Generic competition typically drives prices down significantly. The exact price of Indian generic lenacapavir will depend on manufacturing costs, market competition, and government procurement policies.
For more information, contact IMSDA at contact@indiamedicine.org.